tirzepatide vs semaglutide safety profile Semaglutide: What You Need to Know Switching Semaglutide to Tirzepatide |

Seek immediate medical attention (call 911 for severe symptoms) if you experience: Chest pain, pressure, or discomfort, particularly if new or worsening Severe shortness of breath or difficulty breathing at rest Rapid or irregular heartbeat accompanied by dizziness or lightheadedness Swelling in the legs, ankles, or abdomen that develops suddenly or worsens Unexplained fatigue or exercise intolerance that significantly limits daily activities These symptoms may indicate cardiovascular complications unrelated to tirzepatide itself but requiring urgent evaluation, especially in patients with diabetes and obesity who have elevated baseline cardiovascular risk

"Tirzepatide, a Dual GIP/GLP-1 Receptor Co-agonist for the Treatment of Type 2 Diabetes with Unmatched Effectiveness Regrading Glycaemic Control and Body Weight Reduction." Cardiovascular Diabetology, 2022, 21:169

Paige Verified reviewer Super convenient, and amazing customer service

GIP also works synergistically with GLP-1, amplifying the insulin-sensitizing effects beyond what either receptor achieves alone